KalVista: Filling the VEGF void
KalVista developing kallikrein inhibitors for diabetic macular edema
KalVista Pharmaceuticals Ltd. believes its small molecule plasma kallikrein inhibitors will treat diabetic macular edema on par with VEGF inhibitors and will work in more patients. The biotech also hopes to offer injectable and oral delivery options for clinicians.
Diabetic macular edema (DME) is caused by increased permeability of the retinal vasculature, which results in fluid accumulation in the macula and ultimately vision loss.
First-line therapy includes laser-induced retinal photocoagulation, which can slow or reverse disease progression and reduce